Literature DB >> 32580023

Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics.

Kentaro Inamura1.   

Abstract

The microbiota influences human health and the development of diverse diseases, including cancer. Microbes can influence tumor initiation and development in either a positive or negative manner. In addition, the composition of the gut microbiota affects the efficacy and toxicity of cancer therapeutics as well as therapeutic resistance. The striking impact of microbiota on oncogenesis and cancer therapy provides compelling evidence to support the notion that manipulating microbial networks represents a promising strategy for treating and preventing cancer. Specific microbes or the microbial ecosystem can be modified via a multiplicity of processes, and therapeutic methods and approaches have been evolving. Microbial manipulation can be applied as an adjunct to traditional cancer therapies such as chemotherapy and immunotherapy. Furthermore, this approach displays great promise as a stand-alone therapy following the failure of standard therapy. Moreover, such strategies may also benefit patients by avoiding the emergence of toxic side effects that result in treatment discontinuation. A better understanding of the host-microbial ecosystem in patients with cancer, together with the development of methodologies for manipulating the microbiome, will help expand the frontiers of precision cancer therapeutics, thereby improving patient care. This review discusses the roles of the microbiota in oncogenesis and cancer therapy, with a focus on efforts to harness the microbiota to fight cancer.
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Bacteria; Fecal microbiota transplantation; Immune checkpoint inhibitor; Nanotechnology; Tumor microenvironment

Mesh:

Substances:

Year:  2020        PMID: 32580023     DOI: 10.1016/j.semcancer.2020.06.006

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  4 in total

1.  Association of Fusobacterium nucleatum with Specific T-cell Subsets in the Colorectal Carcinoma Microenvironment.

Authors:  Jennifer Borowsky; Koichiro Haruki; Mai Chan Lau; Andressa Dias Costa; Jochen K Lennerz; Marios Giannakis; Jonathan A Nowak; Shuji Ogino; Juha P Väyrynen; Tomotaka Ugai; Kota Arima; Annacarolina da Silva; Kristen D Felt; Melissa Zhao; Carino Gurjao; Tyler S Twombly; Kenji Fujiyoshi; Sara A Väyrynen; Tsuyoshi Hamada; Kosuke Mima; Susan Bullman; Tabitha A Harrison; Amanda I Phipps; Ulrike Peters; Kimmie Ng; Jeffrey A Meyerhardt; Mingyang Song; Edward L Giovannucci; Kana Wu; Xuehong Zhang; Gordon J Freeman; Curtis Huttenhower; Wendy S Garrett; Andrew T Chan; Barbara A Leggett; Vicki L J Whitehall; Neal Walker; Ian Brown; Mark Bettington; Reiko Nishihara; Charles S Fuchs
Journal:  Clin Cancer Res       Date:  2021-02-25       Impact factor: 13.801

Review 2.  Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies.

Authors:  Yuting Lu; Xiangliang Yuan; Miao Wang; Zhihao He; Hongzhong Li; Ji Wang; Qin Li
Journal:  J Hematol Oncol       Date:  2022-04-29       Impact factor: 23.168

Review 3.  Relationships among microbiota, gastric cancer, and immunotherapy.

Authors:  Yuzhen Li; Xiaona Huang; Desheng Tong; Chenyu Jiang; Xiaodan Zhu; Zhipeng Wei; Tingjie Gong; Chunhui Jin
Journal:  Front Microbiol       Date:  2022-09-12       Impact factor: 6.064

Review 4.  Fungi, host immune response, and tumorigenesis.

Authors:  Miar Elaskandrany; Rohin Patel; Mintoo Patel; George Miller; Deepak Saxena; Anjana Saxena
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-07-07       Impact factor: 4.871

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.